Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.
The presence of high numbers of somatostatin receptors seems to be the basis for the successful control by Sandostatin of hormonal hypersecretion by most growth hormone-secreting pituitary adenomas, endocrine pancreatic tumors, and carcinoids. In this report, we present preliminary data on in vivo somatostatin receptor imaging with a 123I-coupled somatostatin analog (204-090) in patients with these types of tumors.
Lamberts
S W
SW
Department of Medicine, Erasmus University, Rotterdam, The Netherlands.
Bakker
W H
WH
Reubi
J C
JC
Krenning
E P
EP
D002276:Carcinoid Tumor / Q000000981:diagnostic imaging*; D006801:Humans; D007457:Iodine Radioisotopes; D015282:Octreotide / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D009384:Paraneoplastic Endocrine Syndromes / Q000000981:diagnostic imaging*; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D011877:Radionuclide Imaging; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D017481:Receptors, Somatostatin
D007457:Iodine Radioisotopes; D017981:Receptors, Neurotransmitter; D017481:Receptors, Somatostatin; C045210:3-Tyr-octreotide; D015282:Octreotide